Canada Markets open in 4 hrs 56 mins

Ultimovacs ASA (ULTIO.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
77.80+2.90 (+3.87%)
At close: 02:11PM CEST
Full screen
Previous Close74.90
Open77.80
Bid76.60 x N/A
Ask0.00 x N/A
Day's Range77.80 - 77.80
52 Week Range77.80 - 77.80
Volume250
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy

    Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 yearsUV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint inhibition Oslo, 25 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune r

  • GlobeNewswire

    Ultimovacs ASA: First quarter 2022 result presentation

    Oslo, 12 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today. The presentation by the company's management team can be followed as a live webcast at 13:00 CET and will be made available on the website. It will be possible to post questions during the presentation through the webcast. Highlights for the first quarter of 2022: On 22 April 2022, Ultimovacs received a Notice of Allowance

  • GlobeNewswire

    Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting

    UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 yearsMeasurable UV1-specific immune response in 91% of patients when combined with checkpoint inhibitor, as compared to 82% and 67% without checkpoint inhibitorImmune responses induced more rapidly when UV1 was combined with a checkpoint inhibitorDevelopment of UV1-specific immune responses associated with longer survival time Oslo, 10 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULT